video: F. Ciardiello shares his comments on a next generation sequencing study applied to identify genetic alterations in patients with metastatic colorectal cancer who do not develop K-ras mutations during the course of therapy with cetuximab and panitumumab. The analysis revealed a high level of amplification of the MET proto-oncogene. The emergence of MET amplification in circulating, cell-free, DNA may be used to select patients most likely to benefit from anti-MET therapies. http://www.esmo.org view more
Credit: © European Society for Medical Oncology